Amylyx Pharmaceuticals (AMLX) stock

Medicines for diseases , market cap $3.5B

Medicines for diseases

Worth $3.5B

$30.91

+2.32%

As of Tuesday's close · Live for Pro members at the open

Quality Score

Average

In its industry

#68of 281

Biotech

Checks firing

7of 14

Trending up

From 52-week high

-24.9%

under its best in a year

AMLX's Quality Score was unchanged on Tue, Nov 10, at 6.

Follow AMLX's trial news. Pro members can get an alert when Amylyx Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an alert when AMLX files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEnd of 2026“…trial of avexitide in post-bariatric hypoglycemia; New Drug Application submission planned by end of 2026…”Filing with regulators · SEC filing · Nov 5

Why AMLX fell on Nov 5

Down 6.1% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6.3%.

Its Nov 5 results: sales and admin costs were $21.3M, from $16.2M a year before; net loss widened to $45.5M, from $34.4M. It fell 6% on Nov 5.

Sources: Price history, Nov 5, 2026; Company release, Nov 5, 2026

1 more reason, free with an account →1 more reason why AMLX fell on Nov 5, from its filings, with the other side, how the business stands, the timeline, and its peers, for Pro members.

Why AMLX still beats the market over a year

Up 148% over the year to Nov 9 while the S&P 500 rose 12%; down 6% on Nov 5.

2 reasons, from its filings, with the timeline and its peers, for Pro members.

Key facts on AMLX

Key facts on AMLX
Outperforming	Up 151% in a year vs the S&P's +12%
Latest filing	8-K, Nov 5 Reported its quarterly results

1 more reason behind AMLX's 6, free with an account →4 more reasons behind AMLX's 6, for Pro members.

What's next

Tue Nov 10: Stifel Healthcare Conference 2026Investor conference · date confirmed.

1 more date ahead: the conference, for Pro members.

AMLX catalysts

Coming up

After its last 4 reports it closed -2.1% on average, higher 1 of 4 times.

4 past catalysts since 2026, with sizes and sources, for Pro members.

What's next for AMLX, and how long its cash lasts

Next step the company has named

End of 2026“Reported positive topline results from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia; New Drug Application submission planned by end of 2026 remains on track”Filing with regulators · SEC filing · Nov 5

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

Lead program: Avexitide
Another trial: LUMINAPhase 1 · Recruiting · 48 people · main data estimated Feb 2027 · NCT06665165

2 more trials, 2 more milestones and 33 filings, for Pro members.

Cash runway

The company says its cash lasts into 2028 (8-K, Aug 6).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Mar 3, 2026)
At-the-market share sales program (S-3ASR, filed Mar 3, 2026)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

Director George M. Milne Jr. sold 30,000 shares on Oct 5, under a planned sale. 22 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Joshua Cohen buys or sells

For Pro members: every trade, and Joshua Cohen’s 16 filings and quotes.

Get an alert when AMLX files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why AMLX scores 6

Averagefor quality, not price, 7 of 14 chart checks firingWhat the Quality Score means

+7Chart checks 7 of 14 firing right now, one point each
+2Long-term trend above a rising 200-⁠day average

Run-up adds
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
Insider trades subtracts

No effect today: Size, Profit, Growth, Persistence, and News.

What every line is worth, and the reason behind it, on AMLX and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:29 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when AMLX's Quality Score turns up

A free account. No card.

How AMLX ranks in Biotech

AMLX is #68 of 281 by Quality Score.

How AMLX ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	ALXOALX Oncology		Open for its score
	AMGNAmgen		Open for its score
	AMPHAmphastar Pharmaceuticals		Open for its score
	AMRXAmneal Pharmaceuticals		Open for its score
68	AMLXAmylyx Pharmaceuticals	7/14	6

Cash and short-term investments: AMLX $768M, BMRN $736M, AUPH $487M, ARQT $259M.

When does AMLX report earnings, and what happens after?

Expected to report Thu Mar 4, before the open (in 114 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What AMLX reported on Nov 5, 2026

The quarter

A loss of $0.38 a share, from $0.37.

“The increase was primarily due to an increase in spending related to the pivotal Phase 3 LUCIDITY clinical trial and other costs related to avexitide and other programs.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

AMLX's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“This increase was primarily due to an increase in personnel-related costs to support our pre-commercialization activities and the vesting of PSU awards during the quarter.”

From its results filing (SEC filing · Nov 5)

The numbers

Market value: $3.5B; today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on AMLX: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-5.3%+10.7%-6.0%

May 7Aug 6Nov 5

Reported	When	Gap	Reaction	5 days
Nov 5, 2026Before open	Before open	+2.8%	-6.0%	not yet
Aug 6, 2026Before open	Before open	-3.4%	+10.7%	+6.9%
May 7, 2026Before open	Before open	-0.5%	-5.3%	-9.2%

AMLX closed higher after 1 of its last 4 reports.

All 4 reports, and AMLX's Quality Score going into each

AMLX sales and profit by year

Sales and profit by year

Sales grew in one of the last three years, to $0 in 2025. It made a profit in one of the four years.

AMLX has 7 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on AMLX, and all 14 on every stock.Get in free →

AMLX RSI today: 59.5, above its 50-day and 200-day averages

Not scored

RSI 59.5, MACD above signal, above both averages. Not scored.13 readings

The deep dive on AMLX

What it does and how it makes money3 findings"Although no patents have yet issued from this family, we expect the term on patents issuing from this family to extend until at least April 22, 2044, not accounting for any patent term adjustment or extensions or terminal disclaimers, and assuming that all applicable annuity and/or maintenance fees are paid timely." (10-K for fiscal 2025)SEC filing · Mar 3, 2026
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades AMLX, for Pro members
Against its closest peers4 peersCash and short-term investments: AMLX $768M, BMRN $736M, AUPH $487M, ARQT $259M.

4 more findings on AMLX, each with its source, for Pro members.

AMLX share count over time

Shares: 29.0% more than a year ago (to Dec 31).

Shares of AMLX outstanding, as filed
Shares outstanding	As of
128.6M	Oct 26, 2026
111.4M	Jul 27, 2026
111.2M	Apr 27, 2026
110.5M	Feb 23, 2026

Offerings, shelves, and splits of AMLX, from its filings
From its filings	Filed
Raised $500.2M in a sale of shares, about 14% of its market value	Aug 20, 2026
Registered shares for a later sale (S-3ASR)	Mar 3, 2026
Raised $175M in a sale of shares, about 5% of its market value	Sep 10, 2025
Registered shares for a later sale (S-3)	Mar 4, 2025

AMLX insider trades

One insider bought $51K across 1 filing, and 5 insiders sold $2.9M across 10 filings, in the last 6 months. The newest:

SellJoshua B. Cohen$950KCo-Chief Executive Officerat $32.16 on Sep 10, filed Sep 14

SellJoshua B. CohenCo-Chief Executive Officer$950Kat $32.16 on Sep 10, filed Sep 14

All 11 insider filings on AMLX from the last six months, for Pro members.

All AMLX insider trades

AMLX's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Joshua B. CohenCo-Chief Executive Officer · 7 trades
Justin B. KleeCo-Chief Executive Officer · 7 trades
James M. FratesChief Financial Officer · 5 trades
Gina MazzarielloChief Legal Officer · 7 trades
Camille L. BedrosianChief Medical Officer · 4 trades
Karen FirestoneDirector · 2 trades
George M. Milne Jr.Director · 1 trade

See insider trades by person

Which ETFs hold AMLX?

In ETFs: AMLX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

136 employeesCambridge, MAamylyx.com

What Amylyx Pharmaceuticals says it competes with

“The biotechnology and pharmaceutical industries are characterized by rapid technological advancement, significant competition and an emphasis on proprietary products.”

From its annual report, SEC filing · Mar 3, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on AMLX and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move AMLX's score: 7 things
7 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawaySep 14Joshua B. Cohen sold AMLX$950K at $32.16, filed Sep 14

Alerts are optional.

See AMLX's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: AMLX's Quality Score is 6 (Average), #68 of 281 in Biotech. Insiders bought $51K and sold $2.9M in the last 6 months (Form 4).

What does AMLX's Quality Score say?

AMLX scores 6 today, which Breakaway calls Average. It is #68 of 281 in Biotech by Quality Score, with 7 of 14 chart checks firing. Down 6.1% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6.3%. Shares: 29.0% more than a year ago (to Dec 31). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is AMLX's Quality Score?

AMLX scores 6 today, which Breakaway calls Average (6 to 10). That is #68 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AMLX's 6.

Are insiders buying AMLX?

One insider bought $51K across 1 filing, and 5 insiders sold $2.9M across 10 filings, in the last 6 months. The newest is Joshua B. Cohen, Co-⁠Chief Executive Officer, who sold $950K on Sep 10. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.